<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731051</url>
  </required_header>
  <id_info>
    <org_study_id>HYDR0121/CCO</org_study_id>
    <nct_id>NCT04731051</nct_id>
  </id_info>
  <brief_title>The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients</brief_title>
  <official_title>A Pilot, Randomized, Open-label Trial to Determine the Feasibility, Safety, Efficacy, and Pharmacokinetics of Nebulized HCQ01 for the Treatment of Patients With COVID-19 and Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Hussein Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amman Pharmaceutical Industries (API)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sana Pharmaceutical Industry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ACDIMA Biocenter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King Hussein Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, randomized, single-center, parallel group, open-label controlled study to&#xD;
      evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus&#xD;
      Standard of Care (SOC) versus SOC alone in hospitalized cancer patients with COVID-19. King&#xD;
      Hussein Cancer Center (KHCC) is the study sponsor, and the study will be conducted at KHCC&#xD;
      COVID-19 wards.&#xD;
&#xD;
      Approximately 28 cancer patients, ≥18 years of age with a confirmed SARS-CoV-2 infection,&#xD;
      will be enrolled and randomized 1:1 to the treatment and control arms where they will receive&#xD;
      ten doses of Hydroxychloroquine solution via nebulizer in addition to SOC or the control arm&#xD;
      where treatment will follow KHCC SOC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who improve by at least one level lower on the 11-point World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI), where patients are scored on a scale of 0-10 with 0 being uninfected and 10 being dead .</measure>
    <time_frame>Time Frame: Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who improve by at least one level lower on the 11-point WHO-OSCI</measure>
    <time_frame>Days 5, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in condition measured using the 11-point WHO-OSCI</measure>
    <time_frame>Days 5, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hydroxychloroquine (HCQ) concentration in plasma versus time profiles</measure>
    <time_frame>Day 1 pre-dose (time 0) and +2, +5, +10, +15, +20, +25, and +30 minutes after dose, and also +1, +2, +3, +4 and +6 hours post-dose completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Oxygenation as determined by the SpO2 / FiO2 ratio</measure>
    <time_frame>Day 5 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events of HCQ</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Incidence and severity of treatment-related adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Transfer to the Intensive Care Unit</measure>
    <time_frame>Up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Improvement</measure>
    <time_frame>Up to day 28</time_frame>
    <description>time (in days) to improvement in clinical status by at least one level lower on the 11 point WHO-OSCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hrs</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of discharged or not requiring supplemental oxygen</measure>
    <time_frame>Day 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Intensive Care Unit mortality</measure>
    <time_frame>Day 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care length of stay</measure>
    <time_frame>Up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation free days</measure>
    <time_frame>Day 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>Day 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence &amp; duration of new oxygen use</measure>
    <time_frame>Day 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of new mechanical ventilation use</measure>
    <time_frame>Day 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Arrhythmia - Polymorphic Ventricular Tachycardia</measure>
    <time_frame>Up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Arrhythmia - Ventricular Tachycardia</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Cardiologist Diagnostic Documentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Arrhythmia - Lengthening QTc</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Cardiologist Diagnostic Documentation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>2019 Novel Coronavirus</condition>
  <arm_group>
    <arm_group_label>First Arm (Hydroxychloroquine sulfate, 5 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive continued standard of care therapy (SOC) for COVID-19 together with 2 ml HCQ01 (12.5 mg/ml) twice a day for 5 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Arm (Continued Standard of Care (SOC) Therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive continued standard of care therapy for COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCQ01</intervention_name>
    <description>HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization</description>
    <arm_group_label>First Arm (Hydroxychloroquine sulfate, 5 days)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care (SOC) for COVID-19</intervention_name>
    <description>Standard of care (SOC) for COVID-19</description>
    <arm_group_label>First Arm (Hydroxychloroquine sulfate, 5 days)</arm_group_label>
    <arm_group_label>Second Arm (Continued Standard of Care (SOC) Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Documented informed consent of the patient and/or legally authorized representative.&#xD;
             Assent, when appropriate, will be obtained per institutional guidelines.&#xD;
&#xD;
          2. Male or female ≥18 years of age at time of enrolment.&#xD;
&#xD;
          3. History of/ or active histologically or cytologically confirmed diagnosis of&#xD;
             hematological or solid tumor (any type, any stage and any localization).&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Status &lt; or = 3 (Appendix I).&#xD;
&#xD;
          5. Patients must have an active cancer treatment or have completed therapy within 12&#xD;
             months of initiation of protocol specified therapy. This includes:&#xD;
&#xD;
               -  Patients with a new cancer diagnosis who have not yet initiated cancer therapy.&#xD;
&#xD;
               -  Patients on active or have recently completed cancer-directed therapy including&#xD;
                  chemotherapy, targeted therapy, radiation therapy, immunotherapy or hormonal&#xD;
                  therapy amongst others which would not increase the risk of having an adverse&#xD;
                  outcome from participating in this study.&#xD;
&#xD;
          6. Currently hospitalized with laboratory-confirmed SARS-CoV-2 infection as determined by&#xD;
             polymerase chain reaction (PCR) collected within one week prior to randomization.&#xD;
&#xD;
          7. Initial COVID-19 severity status on the WHO 11-point Ordinal Scale for Clinical&#xD;
             Improvement = 4 (&quot;Hospitalized; no oxygen therapy &quot;), = 5 (&quot;Hospitalized; oxygen by&#xD;
             mask or nasal prongs &quot;), or 6 (&quot;Hospitalized; oxygen by NIV or high flow &quot;) (Appendix&#xD;
             II).&#xD;
&#xD;
          8. COVID-19-induced pneumonia evidenced by chest X-ray, computed tomography scan (CT&#xD;
             scan) or magnetic resonance scan (MR scan).&#xD;
&#xD;
          9. Estimated life expectancy of at least 6 months at hospital admission for COVID-19.&#xD;
&#xD;
         10. Patients must be receiving standard of care for SARS-CoV-2.&#xD;
&#xD;
         11. Patients must have an assessment of adequate organ function within 28 days prior to&#xD;
             enrolment, evidenced by:&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g / dL.&#xD;
&#xD;
               -  Leukometry&gt; 2,000 / mm3 (&gt; 2 10E3/ ul).&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500 / mm3 (≥1.5 10E3/ul).&#xD;
&#xD;
               -  Platelet count ≥ 100,000 / mm3 (≥100 10E3/ul).&#xD;
&#xD;
               -  Creatinine clearance ≥ 30 mL / min. Creatinine clearance (CrCl) should be&#xD;
                  calculated according to the Cockcroft-Gault formula.&#xD;
&#xD;
               -  Total bilirubin &lt;3 x the upper limit of normal (ULN), except for patients with&#xD;
                  known Gilbert's syndrome.&#xD;
&#xD;
               -  Aspartate aminotransaminase (AST) &lt;3.0 x LSN.&#xD;
&#xD;
               -  Alanine aminotransaminase (ALT) &lt;3.0 x ULN.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Pregnant (positive β-human chorionic gonadotropin test, β-HCG) or lactating female at&#xD;
             screening.&#xD;
&#xD;
          2. Patients with a history of retinopathy, sickle cell disease or trait, psoriasis,&#xD;
             porphyria, history of splenectomy, mental illness or uncontrolled seizures disorder,&#xD;
             known active tuberculosis or history of incompletely treated tuberculosis, patients on&#xD;
             chronic immunosuppression for other medical conditions such as rheumatological&#xD;
             disorders, inflammatory bowel disease, or in patients with organ transplants.&#xD;
&#xD;
          3. Patients admitted in ICU.&#xD;
&#xD;
          4. Taking medications which may lead to interactions with hydroxychloroquine, including&#xD;
             penicillamine, telbivudine, botulinum toxin, fluconazole, digoxin, propafenone ,&#xD;
             cimetidine, statins, warfarin, and cyclosporine within 2 weeks of dosing start, and&#xD;
             during the duration of the study.&#xD;
&#xD;
          5. History of Glucose-6-phosphate dehydrogenase deficiency.&#xD;
&#xD;
          6. Pre-treatment corrected QT interval (QTc) ≥450 milliseconds.&#xD;
&#xD;
          7. Acute or chronic kidney disease (stage-4 or -5 renal impairment; eGFR&lt;30 mL/min/1.73&#xD;
             m2 or hemodialysis).&#xD;
&#xD;
          8. Liver Child-Pugh grade C.&#xD;
&#xD;
          9. Patients with Hypokalemia (&lt;3.6 mg/dl), Hypocalcemia (&lt;8.8 mg/dl), Hypomagnesemia&#xD;
             (&lt;1.7 mg/dl). Will be included after correction.&#xD;
&#xD;
         10. Need for mechanical ventilation.&#xD;
&#xD;
         11. History of hypersensitivity to hydroxychloroquine.&#xD;
&#xD;
         12. History of Chronic Hepatitis B or hepatitis C infections.&#xD;
&#xD;
         13. History of Human Immunodeficiency Virus (HIV) infection.&#xD;
&#xD;
         14. Concurrent serious illness including, but not limited to, any of the following:&#xD;
&#xD;
               -  Clinically significant cardiovascular disease (e.g., uncontrolled hypertension,&#xD;
                  myocardial infarction, or unstable angina).&#xD;
&#xD;
               -  New York Heart Association class II-IV congestive heart failure.&#xD;
&#xD;
               -  Serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
               -  Peripheral vascular disease ≥ grade 2 within the past year.&#xD;
&#xD;
               -  Psychiatric illness/social situation that would limit compliance with study&#xD;
                  requirements.&#xD;
&#xD;
               -  COPD, Lung cancer, and moderate to severe asthma.&#xD;
&#xD;
         15. Any other significant finding based on the judgment of the PI would increase the risk&#xD;
             of having an adverse outcome from participating in this study.&#xD;
&#xD;
         16. Any other concomitant treatment based on the judgment of the PI would increase the&#xD;
             risk of having an adverse outcome from participating in this study.&#xD;
&#xD;
         17. Is currently participating in or has participated in an interventional clinical trial&#xD;
             with an investigational compound or device within 80 days of signing the informed&#xD;
             consent/assent for this current trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feras Hawari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Hussein Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feras Hawari, MD</last_name>
    <phone>00962796699092</phone>
    <email>fhawari@khcc.jo</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yasmeen Dodin, MSc</last_name>
    <phone>00962798950958</phone>
    <email>YD.14502@KHCC.JO</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <zip>11941</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <contact>
      <last_name>Feras Hawari, MD</last_name>
      <phone>+962796699092</phone>
      <email>fhawari@khcc.jo</email>
    </contact>
    <contact_backup>
      <last_name>Yasmeen Dodin, MSc</last_name>
      <phone>+962798950958</phone>
      <email>YD.14502@KHCC.JO</email>
    </contact_backup>
    <investigator>
      <last_name>Feras Hawari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nasir Idkaidek, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamal AlRabi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mu'taz Labib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deeb Zahran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yasmeen Dodin, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asma Tbakhi, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rabab Tayyem, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samer Najar, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hani Al-Najjar, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Hussein Cancer Center</investigator_affiliation>
    <investigator_full_name>Feras Hawari</investigator_full_name>
    <investigator_title>Consultant in Pulmonary and Critical Care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

